Formed in late 2017, AMLo Biosciences is dedicated to providing a prognostic test for early AJCC Stage I and Stage II melanoma to better identify patients’ true risk of disease progression. 

Biotechnology

AMLo Biosciences

AMLo Biosciences' headquarters in Newcastle upon Tyne, United Kingdom

Marie Labus

Sarah Cockman

Philip Sloan

Helen Pearse

Sandy Primrose

The Leadership Team at AMLo Biosciences is responsible for setting the strategic vision and overseeing the overall direction of the company. Comprised of key executives including the Chief Executive Officer, Chief Scientific Officer, Chief Marketing Officer, and Chief Histopathologist, the team focuses on advancing the development and commercialization of innovative prognostic tests for melanoma, fostering collaboration across departments, and ensuring alignment with the company’s mission to improve patient outcomes through early risk identification.

Leadership Team

The Medical and Scientific Professionals team at AMLo Biosciences is focused on advancing research and validation of prognostic testing for early-stage melanoma. Comprising experts in scientific leadership, histopathology, medical communication, and laboratory operations, this team ensures the accuracy and reliability of diagnostic tools while providing critical insights into disease progression and patient management. Their collective expertise drives the development of innovative solutions to enhance patient outcomes in melanoma care.

Medical and Scientific Professionals

This department ensures product quality and compliance with regulatory standards.

AMLo Biosciences

Org chart

Board & advisors

Teams

Leadership Team

Medical and Scientific Professionals

Quality Assurance and Regulatory

Offices

AMLo Biosciences

Org chart

Board & advisors

Teams

Leadership Team

Medical and Scientific Professionals

Quality Assurance and Regulatory

Offices

Related companies